Stem Cell Therapeutics Overview
- Year Founded
-
2004
- Status
-
Acquired/Merged
- Latest Deal Type
-
M&A
- Financing Rounds
-
2
- Investments
-
1
Stem Cell Therapeutics General Information
Description
Developer of drug based therapies designed for the treatment of central nervous system diseases. The company's drug based therapies utilize drugs to stimulate a patient's own resident stem cells to repair neurological function lost due to diseases such as stroke, traumatic brain injury, multiple sclerosis and other neurodegenerative conditions, enabling the patients to get cured from nervous system disorders.
Contact Information
Website
www.stemcellthera.comCorporate Office
- Bow Valley Square III
- Suite 500 - 255 5th Avenue South West
- Calgary, Alberta T2P 3G6
- Canada
Corporate Office
- Bow Valley Square III
- Suite 500 - 255 5th Avenue South West
- Calgary, Alberta T2P 3G6
- Canada
Stem Cell Therapeutics Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
Stem Cell Therapeutics Patents
Stem Cell Therapeutics Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| US-20090081205-A1 | Continuous dosing regimens for neural stem cell proliferating agents and neural stem cell differentiating agents | Active | 17-Mar-2006 | ||
| US-20070111932-A1 | Method of enhancing and/or inducing neuronal migration using erythropoietin | Inactive | 31-Jul-2003 | ||
| US-20040092448-A1 | Adding to multipotent neural stem cells; treating neurodegenerative disorders and brain injuries | Active | 31-Jul-2002 | ||
| US-7368115-B2 | Adding to multipotent neural stem cells; treating neurodegenerative disorders and brain injuries | Inactive | 31-Jul-2002 | ||
| AU-2003250704-A1 | Method of enhancing and/or inducing neuronal migration using erythropoietin | Inactive | 31-Jul-2002 | A61K38/1808 |
Stem Cell Therapeutics Acquisitions (1)
Stem Cell Therapeutics’s most recent deal was a Reverse Merger with Trillium Therapeutics for . The deal was made on 12-Feb-2013.
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| Trillium Therapeutics | 12-Feb-2013 | Reverse Merger | Drug Discovery |
Stem Cell Therapeutics Exits (1)
Stem Cell Therapeutics’s most recent exit was on 12-Feb-2013 from Trillium Therapeutics. The exit was categorized as .
| Company Name | Exit Date | Exit Type | Exit Size | Status | Buyers |
|---|---|---|---|---|---|
| Trillium Therapeutics | 12-Feb-2013 | Completed |
|
Stem Cell Therapeutics FAQs
-
When was Stem Cell Therapeutics founded?
Stem Cell Therapeutics was founded in 2004.
-
Where is Stem Cell Therapeutics headquartered?
Stem Cell Therapeutics is headquartered in Calgary, Canada.
-
What industry is Stem Cell Therapeutics in?
Stem Cell Therapeutics’s primary industry is Biotechnology.
-
Is Stem Cell Therapeutics a private or public company?
Stem Cell Therapeutics is a Private company.
-
What is Stem Cell Therapeutics’s current revenue?
The current revenue for Stem Cell Therapeutics is .
-
How much funding has Stem Cell Therapeutics raised over time?
Stem Cell Therapeutics has raised $6.94M.
-
When was Stem Cell Therapeutics acquired?
Stem Cell Therapeutics was acquired on 12-Feb-2013.
-
Who acquired Stem Cell Therapeutics?
Stem Cell Therapeutics was acquired by Trillium Therapeutics.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process